Elderly @entity1 , defined as those >or= 70 years of age, represent approximately 40% of all @entity1 diagnosed with @entity1149 in the United States. Nonetheless, elderly @entity1 have been underrepresented in national cooperative group trials, and many do not receive appropriate treatment. Whereas the benefit of systemic chemotherapy in younger @entity1 is accepted by most clinicians, there remains a great deal of skepticism with respect to older @entity1 , who are often labeled unfit for chemotherapy. More recent studies with a special focus on elderly @entity1 demonstrate that these @entity1 indeed benefit from chemotherapy. The landmark Elderly Lung Cancer Vinorelbine Italian Study Group trial and the Multicentre Italian Lung Cancer in the Elderly Study clarified the role of @entity1206 in the treatment of elderly @entity1 . Retrospective and prospective subgroup analyses from selected North American trials suggested that elderly @entity1 also benefit from @entity902 -based combinations. Whether elderly @entity1 should be treated with single-agent versus combination chemotherapy is discussed in this review. The available data suggest that @entity1 should be evaluated for chemotherapy based on their performance status and comorbidities rather than age alone. For elderly @entity1 judged fit to receive combination chemotherapy, @entity3003 -based regimens are a reasonable option. In elderly @entity1 with less than optimal performance status or significant comorbid conditions, single-agent therapy may be more appropriate.

Management of advanced XXXX in elderly populations.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung cancer'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
